TY - JOUR
T1 - Neoadjuvant chemotherapy for patients with locally advanced vulvar cancer
AU - Nooij, Linda
AU - Schaake, Eva
AU - Reyners, Anna
AU - Zijlmans, Henry
AU - Amant, Frédéric
N1 - Publisher Copyright: © 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - PURPOSE OF REVIEW: Studies on treatment options for patients with locally advanced vulvar cancer (LAVC) are scarce, and high-level evidence for a primary treatment choice is lacking. Furthermore, current treatment options are associated with extensive morbidity and high complication rates. More effective treatment options are urgently needed. This review describes current treatment possibilities, focusing on literature regarding neoadjuvant chemotherapy (NACT) followed by surgery. RECENT FINDINGS: Although data are heterogeneous and limited, NACT followed by surgery might be an effective and well tolerated treatment alternative associated with lower morbidity compared with current treatment options, such as excenterative surgery or definitive chemoradiation. SUMMARY: Up until now, several studies describe an overall response rate of 40-86%. Surgery turned out to be possible in 40-90% of the LAVC patients who received NACT. Prospective studies on the efficacy and safety of NACT followed by surgery with a homogeneous chemotherapy regimen are urgently awaited. NACT should, at this point, still be considered investigational.
AB - PURPOSE OF REVIEW: Studies on treatment options for patients with locally advanced vulvar cancer (LAVC) are scarce, and high-level evidence for a primary treatment choice is lacking. Furthermore, current treatment options are associated with extensive morbidity and high complication rates. More effective treatment options are urgently needed. This review describes current treatment possibilities, focusing on literature regarding neoadjuvant chemotherapy (NACT) followed by surgery. RECENT FINDINGS: Although data are heterogeneous and limited, NACT followed by surgery might be an effective and well tolerated treatment alternative associated with lower morbidity compared with current treatment options, such as excenterative surgery or definitive chemoradiation. SUMMARY: Up until now, several studies describe an overall response rate of 40-86%. Surgery turned out to be possible in 40-90% of the LAVC patients who received NACT. Prospective studies on the efficacy and safety of NACT followed by surgery with a homogeneous chemotherapy regimen are urgently awaited. NACT should, at this point, still be considered investigational.
KW - definitive chemoradiation
KW - locally advanced vulvar cancer
KW - neoadjuvant chemotherapy followed by surgery
UR - http://www.scopus.com/inward/record.url?scp=85135768997&partnerID=8YFLogxK
U2 - https://doi.org/10.1097/CCO.0000000000000861
DO - https://doi.org/10.1097/CCO.0000000000000861
M3 - Review article
C2 - 35943437
SN - 1040-8746
VL - 34
SP - 466
EP - 472
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 5
ER -